Point72 Asia Hong Kong Ltd increased its holdings in Eli Lilly and Company (NYSE:LLY) by 237.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,761 shares of the company’s stock after purchasing an additional 1,239 shares during the period. Point72 Asia Hong Kong Ltd’s holdings in Eli Lilly and were worth $148,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Sunbelt Securities Inc. lifted its holdings in Eli Lilly and by 0.5% in the 1st quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock worth $313,000 after purchasing an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC lifted its holdings in Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after purchasing an additional 19 shares in the last quarter. Pillar Pacific Capital Management LLC lifted its holdings in Eli Lilly and by 0.3% in the 1st quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock worth $595,000 after purchasing an additional 20 shares in the last quarter. Guardian Life Insurance Co. of America lifted its holdings in Eli Lilly and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock worth $315,000 after purchasing an additional 25 shares in the last quarter. Finally, Rehmann Capital Advisory Group lifted its holdings in Eli Lilly and by 0.9% in the 1st quarter. Rehmann Capital Advisory Group now owns 5,026 shares of the company’s stock worth $423,000 after purchasing an additional 43 shares in the last quarter. 75.77% of the stock is currently owned by institutional investors.

Eli Lilly and Company (NYSE LLY) traded down 0.75% during trading on Monday, hitting $82.30. The stock had a trading volume of 2,059,182 shares. The company has a market cap of $86.83 billion, a PE ratio of 35.61 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The company’s 50 day moving average is $80.88 and its 200-day moving average is $82.06.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the firm posted $0.86 EPS. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a dividend of $0.52 per share. The ex-dividend date was Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.51%. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/11/eli-lilly-and-company-lly-shares-bought-by-point72-asia-hong-kong-ltd.html.

LLY has been the topic of a number of research analyst reports. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and issued a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a report on Tuesday, July 4th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $88.07.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total transaction of $17,730,300.00. Following the completion of the transaction, the insider now directly owns 124,265,804 shares of the company’s stock, valued at approximately $10,491,761,831.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 825,000 shares of company stock valued at $68,456,650 over the last three months. 0.20% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.